Marinus Pharmaceuticals Inc

NASDAQ:MRNS   3:59:58 PM EDT
11.18
-0.12 (-1.06%)
Products

FDA Accepts For Filing And Priority Review Marinus' NDA For Ganaxolone In CDKL5 Deficiency Disorder

Published: 09/20/2021 11:48 GMT
Marinus Pharmaceuticals Inc (MRNS) - Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in Cdkl5 Deficiency Disorder.
Marinus Pharmaceuticals Inc - FDA Indicated That It is Not Currently Planning to Hold an Advisory Committee Meeting for Application.
Marinus Pharmaceuticals Inc - NDA Filing Acceptance Enables Opportunity to Draw $30 Million of Additional Cash Under Company's Credit Financing Agreement.